Current Progress

Submission received

NMG meeting

AWMSG meeting

Ministerial Ratification

AWMSG advice

Fixed dose abacavir and lamivudine (Kivexa®) is recommended as an option for use within NHS Wales in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV-1) infection in adults and adolescents from 12 years of age.
Use should be in accordance with the British HIV Association (BHIVA) guidance. Fixed dose abacavir and lamivudine (Kivexa®) is not suitable for shared care within NHS Wales.